Immune‐modulator Metallo‐peptide (IMMP) effect on an in vivo model of Rheumatoid Arthritis

Abstract

The management of rheumatoid arthritis (RA) has witnessed significant changes over the past decade. The ambition to improve outcomes further, minimize safety concerns and provide more convenient means of administration are all factors that continue to drive continued drug development. The new emerging therapies for the management of RA illustrate much diversity, both in terms of both drug technology as well as the immunological target. Immuno‐modulator metallopeptides (IMMP) is a new factor that could act as biological drug for the management of RA. Our aim is to evaluate IMMP effect on an in vivo model of autoimmune RA. RA in Wistar rats was induced by administration of bovine collagen II. IMMP (50 ng/Kg), i.p., three times a week for 21 days was administrated to Wistar females rats with bovine collagen II‐induced arthritis. The IMMP treatment eliminated all inflammation in 25% of rats, in addition, the treatment reduced the inflammation in 50 % on other 25 % of rats, and meanwhile the remaining 50 % of animals there were no changes. anti‐inflammatory effect. IMMP treatment decreased the breakdown of bone and cartilage, as well as serum levels of the pro‐inflammatory cytokine IL‐4. Histological studies showed that IMMP did not produce alterations in the lymphoid tissues, as well as other organs.